Complete genome and comparative analysis of Streptococcus gallolyticus subsp. gallolyticus, an emerging pathogen of infective endocarditis

Hinse, Dennis; Vollmer, Tanja; Rückert, Christian; Blom, Jochen; Kalinowski, Jörn; Knabbe, Cornelius; Dreier, Jens

doi:10.1186/1471-2164-12-400

Cited by 40 publications

(37 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These genes encode for a lantibiotic that share high degree of similarity with Smb and haloduracin. Hinse et al (56) have shown that the BAA-2069 strain indeed produces a lantibiotic that is active. Therefore, we tested S. mutans V403, S. sanguinis SK36, and S. pyogenes JRS4 strains overexpressing SmbFT or containing the vector.…”

Section: Resultsmentioning

confidence: 99%

SmbFT, a Putative ABC Transporter Complex, Confers Protection against the Lantibiotic Smb in Streptococci

Biswas

2013

J Bacteriol

View full text Add to dashboard Cite

Streptococcus mutans, a dental pathogen, secretes different kinds of lantibiotic and nonlantibiotic bacteriocins. For self-protection, a bacteriocin producer strain must possess one or more cognate immunity mechanisms. We report here the identification of one such immunity complex in S. mutans strain GS-5 that confers protection against Smb, a two-component lantibiotic. The immunity complex that we identified is an ABC transporter composed of two proteins: SmbF (the ATPase component) and SmbT (the permease component). Both of the protein-encoding genes are located within the smb locus. We show that GS-5 becomes sensitized to Smb upon deletion of smbT, which makes the ABC transporter nonfunctional. To establish the role SmbFT in providing immunity, we heterologously expressed this ABC transporter complex in four different sensitive streptococcal species and demonstrated that it can confer resistance against Smb. To explore the specificity of SmbFT in conferring resistance, we tested mutacin IV (a nonlantibiotic), nisin (a single peptide lantibiotics), and three peptide antibiotics (bacitracin, polymyxin B, and vancomycin). We found that SmbFT does not recognize these structurally different peptides. We then tested whether SmbFT can confer protection against haloduracin, another two-component lantibiotic that is structurally similar to Smb; SmbFT indeed conferred protection against haloduracin. SmbFT can also confer protection against an uncharacterized but structurally similar lantibiotic produced by Streptococcus gallolyticus. Our data suggest that SmbFT truly displays immunity function and confer protection against Smb and structurally similar lantibiotics.

show abstract

Section: Resultsmentioning

confidence: 99%

SmbFT, a Putative ABC Transporter Complex, Confers Protection against the Lantibiotic Smb in Streptococci

Biswas

2013

J Bacteriol

View full text Add to dashboard Cite

show abstract

“…AP012053.1), and ATCC BAA-2069 (accession no. FR824043) were compared by using the EDGAR software to identify genes they have in common (20)(21)(22)(23). From the resulting gene pool, a set of 22 housekeeping genes were selected on the basis of the variability and length (Ͼ500 bp) of DNA sequences or usage in other MLST schemes.…”

Section: Methodsmentioning

confidence: 99%

Development and Application of a Multilocus Sequence Typing Scheme for Streptococcus gallolyticus subsp. gallolyticus

et al. 2014

View full text Add to dashboard Cite

Streptococcus gallolyticus subsp. gallolyticus (formerly known as S. bovis biotype I) is a commensal of the gastrointestinal tract in animals and in up to 15% of healthy humans. Furthermore, it is a facultative pathogen that can cause infectious endocarditis, mastitis, and septicemia. The number of infections is increasing, but the transmission routes and zoonotic potential remain unknown. To assess the zoonotic potential and characterize the epidemiological structure of S. gallolyticus subsp. gallolyticus, we established a multilocus sequence typing (MLST) scheme. We amplified and sequenced internal fragments of seven housekeeping genes. The resulting sequences were analyzed with BioNumerics software 6.6 by using the unweighted-pair group method using average linkages algorithm. A total of 101 S. gallolyticus subsp. gallolyticus strains isolated from animals, humans, and environmental samples were analyzed and divided into 50 sequence types. Our first results highlight the importance of this MLST scheme for investigating the epidemiology, transmission patterns, and infection chains of S. gallolyticus subsp. gallolyticus.

show abstract

“…Surprisingly, a D test positivity rate of 89% for clindamycin-susceptible, erythromycin-resistant isolates was observed in one study (34), and all S. bovis group isolates in another study exhibited low-level resistance to the aminoglycosides (36). A high percentage of tetracycline resistance reported by Beck et al (9) may be possibly explained by the recent identification of pSGG1, a novel plasmid carrying genes for tetracycline resistance that has strong sequence similarities to plasmids and chromosomes in several ruminal and gastrointestinal bacteria, thus suggesting a potential for horizontal gene transfer (40). Future genomic studies may highlight other potential mechanisms of resistance.…”

Section: Antimicrobial Susceptibilitymentioning

confidence: 96%

“…Several contradictory results have been published in the S. bovis group literature, with unreliable 16S rRNA gene and sodA sequences of type strains deposited in GenBank (9,37). Many anticipate that use of new approaches, such as whole-genome sequencing, may result in another reevaluation of taxonomic status in the future (40). Keeping up to date with these changes and understanding their clinical relevance will be imperative for clinical microbiologists and infectious disease physicians alike.…”

Section: Genomic Analysismentioning

confidence: 99%

An Update on the Streptococcus bovis Group: Classification, Identification, and Disease Associations

Dekker

Lau

2016

J Clin Microbiol

View full text Add to dashboard Cite

The Streptococcus bovis group has undergone significant taxonomic changes over the past 2 decades with the advent of new identification methods with higher discriminatory power. Although the current classification system is not yet embraced by all researchers in the field and debate remains over the performance of molecular techniques for identification to the species level within the group, important disease associations for several members of the group have been clarified. Here, we provide a brief overview of the history of the S. bovis group, an outline of the currently accepted classification scheme, a review of associated clinical syndromes, and a summary of the performance and diagnostic accuracy of currently available identification methods.

show abstract

Complete genome and comparative analysis of Streptococcus gallolyticus subsp. gallolyticus, an emerging pathogen of infective endocarditis

Cited by 40 publications

References 59 publications

SmbFT, a Putative ABC Transporter Complex, Confers Protection against the Lantibiotic Smb in Streptococci

SmbFT, a Putative ABC Transporter Complex, Confers Protection against the Lantibiotic Smb in Streptococci

Development and Application of a Multilocus Sequence Typing Scheme for Streptococcus gallolyticus subsp. gallolyticus

An Update on the Streptococcus bovis Group: Classification, Identification, and Disease Associations

Contact Info

Product

Resources

About